{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000030","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.625274+00:00","generated_at":"2026-06-14T04:29:09.647472+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Ligand annual meeting elects 7 directors, ratifies auditor, approves say-on-pay","bullets":["All seven director nominees elected; Jason M. Aryeh received 7,967,581 for vs 6,131,999 withheld.","Ratification of Ernst & Young as auditor passed with 15,512,124 for, 347,261 against.","Non-binding advisory vote on executive compensation approved: 12,379,762 for, 1,698,528 against.","Stockholders chose every-year frequency for say-on-pay votes (13,490,718 for 1 year)."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000030","json":"https://secwatch.observer/filing/0000886163-23-000030.json","markdown":"https://secwatch.observer/filing/0000886163-23-000030.md","text":"https://secwatch.observer/filing/0000886163-23-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000030/0000886163-23-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000030/lgnd-20230609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:29:09.647472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d0543a4ebf2085194c124c98a1d83e856908011","claim":"LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers at the 2023-06-09 meeting.","evidence_excerpt":"Proposal 3 . The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers. In accordance with the results below, the resolution was approved. Votes For Votes Against Abstentions Broker Non-Votes 12,379,762 1,698,528 21,290 1,765,888","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000030/0000886163-23-000030-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"3603462929da81161dd9da26f99a42081d1b54e1","claim":"LIGAND PHARMACEUTICALS INC shareholders approved Election of seven members of the Board of Directors for terms expiring at the 2024 annual meeting at the 2023-06-09 meeting.","evidence_excerpt":"Proposal 1. The election of seven members of the Board of Directors of the Company for terms expiring at the 2024 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director. Votes For Votes Withheld Broker Non-Votes Jason M. Aryeh 7,967,581 6,131,999 1,765,888 Todd C. Davis 13,729,132 370,448 1,765,888 Nancy R. Gray, Ph.D. 13,426,347 673,233 1,765,888 Jason Haas 13,450,640 648,940 1,765,888 John W. Kozarich, Ph.D. 9,920,043 4,179,537 1,765,888 John L. LaMattina, Ph.D. 13,372,521 727,059 1,765,888 Stephen L. Sabba, M.D. 13,313,876 785,704 1,765,888","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000030/0000886163-23-000030-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"59910ca759d549a5c3d94d291d5c75af6fc5c8b5","claim":"LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the frequency of the advisory vote on the compensation of the Company's named executive officers at the 2023-06-09 meeting.","evidence_excerpt":"Proposal 4 . The approval of a non-binding advisory resolution regarding the frequency of the advisory vote on the compensation of the Company’s named executive officers. Based on the results below, the Company has determined that it will hold a stockholder advisory vote on the compensation of the Company’s named executive officers every year. 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 13,490,718 29,347 567,460 12,055 1,765,888","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000030/0000886163-23-000030-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"7e717d1ded8bc7d1eb2fe27b1d8744337a561e8d","claim":"LIGAND PHARMACEUTICALS INC shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-09 meeting.","evidence_excerpt":"Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. In accordance with the results below, the selection of Ernst & Young LLP was ratified. Votes For Votes Against Abstentions Broker Non-Votes 15,512,124 347,261 6,083 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000030/0000886163-23-000030-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}